These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 13959207)

  • 21. Clinical efficacy of heparin fractions: issues and answers.
    Messmore HL
    Crit Rev Clin Lab Sci; 1986; 23(2):77-94. PubMed ID: 2419035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A HEMOSTATIC PROFILE FOR PREOPERATIVE SCREENING OF PATIENTS.
    STEFANINI M
    Arch Otolaryngol; 1965 Sep; 82():310-1. PubMed ID: 14327037
    [No Abstract]   [Full Text] [Related]  

  • 23. Disappearance of factor V activity after incubation of plasm with heparin and heparinoids.
    HOLEMANS R; VERMYLEN C; VERSTRAETE M
    Thromb Diath Haemorrh; 1960 Jun; 4():303-22. PubMed ID: 14402588
    [No Abstract]   [Full Text] [Related]  

  • 24. Anticoagulation management during multivessel coronary artery bypass grafting: a randomized trial comparing individualized heparin management and conventional hemostasis management.
    Hoenicka M; Rupp P; Müller-Eising K; Deininger S; Kunert A; Liebold A; Gorki H
    J Thromb Haemost; 2015 Jul; 13(7):1196-206. PubMed ID: 25954849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A quantitative study of heparin (or heparinoids) in blood plasma of obstetrical and gynecological patients. (Hemorrhage and blood coagulation in obstetrics and gynecology. 11)].
    KIKUCHI I
    J Jpn Obstet Gynecol Soc; 1962 Apr; 14():287-96. PubMed ID: 14455885
    [No Abstract]   [Full Text] [Related]  

  • 27. [Anticoagulant medication. II. Heparin and synthetic heparinoids].
    RICHON J; LECONTE DES FLORIS R
    Concours Med; 1960 Oct; 82():4377-82. PubMed ID: 13741363
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect in man of a new heparinoid, treburon.
    FIELD JB; RAMSAY GD; ATTYAH AM; STARR P
    J Lab Clin Med; 1953 Feb; 41(2):208-14. PubMed ID: 13035252
    [No Abstract]   [Full Text] [Related]  

  • 29. [Opportunity to use heparinoid or dicumarolic substances in the treatment of gynecological thromboembolism; thromboelastographic study of various anticoagulants].
    FERRARO C; STURA L
    Pathologica; 1955; 47(727-728):77-84. PubMed ID: 13322480
    [No Abstract]   [Full Text] [Related]  

  • 30. [The increase of thrombin inhibitor in the blood after percutaneous administration of a heparinoid].
    WITTE S; BRESSEL D
    Klin Wochenschr; 1960 May; 38():501. PubMed ID: 13845470
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.
    Bar J; David A; Khader T; Mulcare M; Tedeschi C
    Prehosp Disaster Med; 2017 Oct; 32(5):580-587. PubMed ID: 28625215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CONTRIBUTION TO THE MANAGEMENT OF VENOUS THROMBOSES AND THROMBOPHLEBITIS].
    ZAWODSKY L
    Wien Med Wochenschr; 1964 Jul; 114():525-9. PubMed ID: 14236494
    [No Abstract]   [Full Text] [Related]  

  • 33. [Changes of blood cholesterol and lipid level in atherosclerotic patients treated with a new heparinoid lacking anticoagulant action].
    SABELLA G; DE SIMONE M
    Clin Ter; 1960 Apr; 18():395-412. PubMed ID: 14440551
    [No Abstract]   [Full Text] [Related]  

  • 34. [Anticurarimimetic action of heparin and synthetic heparinoids in the rabbit].
    CHEYMOL J; BOURILLET F; LEVASSORT C
    J Physiol (Paris); 1955; 47(1):132-6. PubMed ID: 13243278
    [No Abstract]   [Full Text] [Related]  

  • 35. A trial with a physiological heparinoid in some sclerotic chorioretinopathies. An evaluation based on serum cholesterol and lipoprotein values and on clinical ocular findings.
    VANNAS S; KRAUSE U
    Acta Ophthalmol (Copenh); 1961; 39():466-74. PubMed ID: 13780180
    [No Abstract]   [Full Text] [Related]  

  • 36. A new synthetic anticoagulant (heparinoid) preliminary report of its action in humans.
    SORENSON CW; SEIFTER J; WRIGHT IS
    Bull N Y Acad Med; 1949 Jul; 25(7):448. PubMed ID: 18152256
    [No Abstract]   [Full Text] [Related]  

  • 37. [Use of hemostatic preparations in obstetrical hemorrhages].
    Pavlovskiĭ DP; Mikaĭlenko ET
    Pediatr Akus Ginekol; 1976; (1):33-7. PubMed ID: 787905
    [No Abstract]   [Full Text] [Related]  

  • 38. [ENDOGENOUS FIBRINOLYTIC POTENTIAL AND ITS STIMULATION BY A POLYSACCHARIDE ESTER].
    HALSE D
    Hemostase; 1963; 3():149-64. PubMed ID: 14050812
    [No Abstract]   [Full Text] [Related]  

  • 39. [Heparin, low molecular weight heparin, heparinoid, and antithrombin III therapy of disseminated intravascular coagulation].
    Nakagawa M
    Nihon Rinsho; 1993 Jan; 51(1):87-92. PubMed ID: 7679453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
    Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
    Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.